{"protocolSection": {"identificationModule": {"nctId": "NCT01696214", "orgStudyIdInfo": {"id": "ARCTC-09"}, "secondaryIdInfos": [{"id": "IR34HL109482-01A1", "type": "OTHER_GRANT", "domain": "National Heart, Lung, and Blood Institute (NHLBI)"}], "organization": {"fullName": "University of California, San Diego", "class": "OTHER"}, "briefTitle": "A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial", "officialTitle": "SAPS:Smoking Asthmatics Pilot Study:", "acronym": "SAPS"}, "statusModule": {"statusVerifiedDate": "2019-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10"}, "primaryCompletionDateStruct": {"date": "2015-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-06-25", "studyFirstSubmitQcDate": "2012-09-27", "studyFirstPostDateStruct": {"date": "2012-09-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-08-08", "resultsFirstSubmitQcDate": "2016-10-03", "resultsFirstPostDateStruct": {"date": "2016-10-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-01-02", "lastUpdatePostDateStruct": {"date": "2019-01-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Joe Ramsdell", "investigatorTitle": "Medical Doctor", "investigatorAffiliation": "University of California, San Diego"}, "leadSponsor": {"name": "University of California, San Diego", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary aim of the pilot (SAPS) protocol is to determine the feasibility and utility of implementing the provisional design of the full scale TOM trial (e.g., the six month treatment period, the impact of the smoking cessation intervention).\n\nThere is no active hypothesis for the Vanguard Protocol.", "detailedDescription": "The protocol is a small scale pilot of the full-scale TOM trial, and it will utilize a placebo design and incorporates 4 treatment arms. In the Vanguard Protocol all participants are to complete a 4 week run-in with Advair 100/50, followed by randomization to 1 of 4 arms of study treatment. The 4 drug treatment combinations are (2 inhalers, 2 pills):\n\n* Advair 250/50, Placebo, Placebo, Placebo\n* Advair 100/50 and montelukast, Placebo, Placebo\n* Advair 100/50 and theophylline, Placebo, Placebo\n* Advair 100/50 and ipratropium, Placebo, Placebo The 24 week treatment phase will be followed by a 4 week washout period on Advair 100/50. There is no crossover."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma,smokers"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "FACTORIAL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 20, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ipratropium", "type": "PLACEBO_COMPARATOR", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.", "interventionNames": ["Drug: ipratropium"]}, {"label": "Theophylline", "type": "PLACEBO_COMPARATOR", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.", "interventionNames": ["Drug: Theophylline 400 mg"]}, {"label": "Montelukast", "type": "PLACEBO_COMPARATOR", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.", "interventionNames": ["Drug: Montelukast 10mg"]}, {"label": "fluticasone 250 mg/salmeterol 50mg", "type": "PLACEBO_COMPARATOR", "description": "Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.", "interventionNames": ["Drug: Fluticasone 250 mg/salmeterol 50 mg"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone 250 mg/salmeterol 50 mg", "description": "Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo", "armGroupLabels": ["fluticasone 250 mg/salmeterol 50mg"], "otherNames": ["Advair(fluticasone/salmeterol)250/50"]}, {"type": "DRUG", "name": "Montelukast 10mg", "description": "Participants will be assigned to montelukast once a day for 24 weeks.", "armGroupLabels": ["Montelukast"], "otherNames": ["Singulair"]}, {"type": "DRUG", "name": "Theophylline 400 mg", "description": "Participants will be assigned to theophylline once a day for 24 weeks", "armGroupLabels": ["Theophylline"]}, {"type": "DRUG", "name": "ipratropium", "description": "Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.", "armGroupLabels": ["Ipratropium"], "otherNames": ["Atrovent"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Control Test", "description": "The primary symptomatic measure, the Asthma Control Test (ACT), has been shown to be valid for measuring poor asthma control in asthmatic children and non-smoking adults. The ACT is a tool developed by Nathan and collaborators a decade ago for evaluating asthma control. It consists of five questions with five possible answers each. A maximum score of 25 points indicates complete asthma control. A score between 20 and 24 represents partially controlled asthma, while a score 19 or below indicates poorly controlled asthma and a score \\<16 indicates uncontrolled asthma. The minimally important clinical difference has been determined to be 3.", "timeFrame": "Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and at follow-up visit 1 month off study drug. Median scores over the 24 weeks of treatment were compared."}], "secondaryOutcomes": [{"measure": "The Asthma Symptom Utility Index (ASUI)", "description": "The Asthma Symptom Utility Index (ASUI), an important secondary outcome in the proposed full-scale TOM Trial, has also been shown to be useful in tracking the frequency and severity of asthma-related symptoms in non-smoking asthmatics. ASUI is a brief, interviewer-administered, patient preference-based scale assessing frequency and severity of selected asthma-related symptoms and treatment side effects. 11 items are reviewed, with 2-week recall to assess four symptoms (cough, wheeze, shortness of breath, and awakening at night) and medication side-effects each on two dimensions (frequency and severity). 4-point Likert scale is used to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe). Scores range from 0 (worst possible symptoms) to 1 (no symptoms). The change between two time points, initial visit and after 24 weeks of treatment, is reported. The median value is reported with the standard deviation.", "timeFrame": "Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and a follow-up visit 1 month off study drug. Median scores, change from initial visit and end of treatment, were compared"}, {"measure": "Percent (%) Perdicted FEV1 Changes", "description": "Physiologic measures of % predicted FEV1", "timeFrame": "Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks. Median scores over the 24 weeks of treatment were compared"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Gender and Age:\n* Males and females, ages 18- 50\n\nCurrent Smoker:\n\n* Smoke at least 5 cigarettes per day for at least 5 years\n* Positive urine cotinine test\n\nAsthma:\n\n* Physician diagnosed asthma\n* Symptomatic, as evidenced by\n\n  * Use of SABA two or more times per week for relief of asthma symptoms, or\n  * One or more nocturnal awakenings per week for asthma symptoms ACRC - SC MEETING - 19 MAY 2012 SAPS \u2502 25 Confidential, not for attribution or citation.\n* Pre-BD FEV1 greater than or equal to 40% predicted\n* Asthma diagnosis confirmed by either\n\n  * albuterol reversibility of FEV1 by 12% or more, or\n  * 20% fall in FEV1 at 8mg or less of methacholine\n* If over age 45, a DLco greater than 80% predicted\n* Females of childbearing potential: not pregnant, not lactating and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.\n\nExclusion Criteria:\n\n* Diagnosis of COPD or emphysema\n* Other major chronic illnesses in the opinion of the investigator that might interfere with the study:\n\n  - e.g. including but not limited to uncontrolled diabetes, uncontrolled HIV infection or other immune system disorder, hyperthyroidism, seizure disorders, renal failure, liver disease, non-skin cancer, unstable psychiatric illness.\n* Recent active substance abuse (in past 6 months)\n* Lung disease other than asthma including COPD, bronchiectasis, sarcoidosis, or other significant lung disease\n* Unstable cardiac disease (decompensated CHF, unstable angina, recent MI, atrial fibrillation, supraventricular or ventricular tachycardia, congenital heart disease, or severe uncontrolled hypertension).\n* High risk of near fatal or fatal asthma as defined by the following 1-3\n\n  * ICU admission of asthma in the past year\n  * more than 2 hospitalizations for asthma in the previous year\n  * more than 3 ED visits for asthma in the previous year\n  * intubation or ICU admission for asthma in the past 2 years\n  * use of more than 2 canisters of inhaled short-acting beta2-agonist in past month\n* Acute asthma exacerbation in the past 4 weeks (treatment with systemic corticosteroids)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Joe Ramsdell, MD", "affiliation": "UCSD", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Airway Research & Clinical Trials Center", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "results will be presented been publication four-minute meetings"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Ipratropium", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 0.02% solution, 2.5 ml via mini nebulizer for 24 weeks with placebo theophylline and placebo montelukast.\n\nIpratropium: Participants will be assigned to ipratropium 0.02% solution, 2.5 ml via mini nebulizer 3 times"}, {"id": "FG001", "title": "Theophylline", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.\n\nTheophylline: Participants will be assigned to theophylline 400 mg once a day for 24 weeks"}, {"id": "FG002", "title": "Montelukast", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.\n\nMontelukast 10mg: Participants will be assigned to montelukast 10 mg once a day for 24 weeks."}, {"id": "FG003", "title": "Fluticasone 250 mg/Salmeterol 50mg", "description": "Participants will be assigned to inhaled fluticasone 250 mg/salmeterol 50 mg twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.\n\nFluticasone 250 mg/salmeterol 50 mg:\n\nParticipants will be assigned to a 24 week treatment with inhaled fluticasone 250 mg /salmeterol 50"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "smoking asthmatics", "groups": [{"id": "BG000", "title": "Ipratropium", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 0.02% solution, 2.5 ml via mini nebulizer for 24 weeks with placebo theophylline and montelukast.\n\nIpratropium: Participants will be assigned to ipratropium 0.02% solution, 2.5 ml via mini nebulizer 3 times"}, {"id": "BG001", "title": "Theophylline", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 300 mg once a day for 24 weeks with placebo tiotroprium and montelukast.\n\nTheophylline: Participants will be assigned to theophylline 300 mg once a day for 24 weeks"}, {"id": "BG002", "title": "Montelukast", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and tiotroprium.\n\nMontelukast 10mg: Participants will be assigned to montelukast 10 mg once a day for 24 weeks."}, {"id": "BG003", "title": "Fluticasone 250 mg/Salmeterol 50mg", "description": "Participants will be assigned to inhaled fluticasone 250 mg/salmeterol 50 mg twice a day for 24 weeks with placebo theophylline, tiotroprium, and montelukast.\n\nFluticasone 250 mg/salmeterol 50 mg:\n\nParticipants will be assigned to a 24 week treatment with inhaled fluticasone 250 mg /salmeterol 50"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "19"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "19"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49", "lowerLimit": "42", "upperLimit": "50"}, {"groupId": "BG001", "value": "48", "lowerLimit": "44", "upperLimit": "50"}, {"groupId": "BG002", "value": "39", "lowerLimit": "28", "upperLimit": "50"}, {"groupId": "BG003", "value": "28", "lowerLimit": "26", "upperLimit": "50"}, {"groupId": "BG004", "value": "41", "lowerLimit": "26", "upperLimit": "50"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "10"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "9"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "19"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Control Test", "description": "The primary symptomatic measure, the Asthma Control Test (ACT), has been shown to be valid for measuring poor asthma control in asthmatic children and non-smoking adults. The ACT is a tool developed by Nathan and collaborators a decade ago for evaluating asthma control. It consists of five questions with five possible answers each. A maximum score of 25 points indicates complete asthma control. A score between 20 and 24 represents partially controlled asthma, while a score 19 or below indicates poorly controlled asthma and a score \\<16 indicates uncontrolled asthma. The minimally important clinical difference has been determined to be 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "units on a scale", "timeFrame": "Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and at follow-up visit 1 month off study drug. Median scores over the 24 weeks of treatment were compared.", "groups": [{"id": "OG000", "title": "Ipratropium", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and montelukast.\n\nipratropium: Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks."}, {"id": "OG001", "title": "Theophylline", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and montelukast.\n\nTheophylline 400 mg: Participants will be assigned to Theophylline once a day for 24 weeks"}, {"id": "OG002", "title": "Montelukast", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and ipratropium.\n\nMontelukast 10mg: Participants will be assigned to Leukotriene receptor antagonist once a day for 24 weeks."}, {"id": "OG003", "title": "Fluticasone 250 mg/Salmeterol 50mg", "description": "Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, ipratropium, and montelukast.\n\nFluticasone 250 mg/salmeterol 50 mg: Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.5", "lowerLimit": "13", "upperLimit": "19"}, {"groupId": "OG001", "value": "13", "lowerLimit": "7", "upperLimit": "19"}, {"groupId": "OG002", "value": "12", "lowerLimit": "9", "upperLimit": "15"}, {"groupId": "OG003", "value": "10", "lowerLimit": "5", "upperLimit": "13"}]}]}]}, {"type": "SECONDARY", "title": "The Asthma Symptom Utility Index (ASUI)", "description": "The Asthma Symptom Utility Index (ASUI), an important secondary outcome in the proposed full-scale TOM Trial, has also been shown to be useful in tracking the frequency and severity of asthma-related symptoms in non-smoking asthmatics. ASUI is a brief, interviewer-administered, patient preference-based scale assessing frequency and severity of selected asthma-related symptoms and treatment side effects. 11 items are reviewed, with 2-week recall to assess four symptoms (cough, wheeze, shortness of breath, and awakening at night) and medication side-effects each on two dimensions (frequency and severity). 4-point Likert scale is used to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe). Scores range from 0 (worst possible symptoms) to 1 (no symptoms). The change between two time points, initial visit and after 24 weeks of treatment, is reported. The median value is reported with the standard deviation.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and a follow-up visit 1 month off study drug. Median scores, change from initial visit and end of treatment, were compared", "groups": [{"id": "OG000", "title": "Ipratropium", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.\n\nipratropium: Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks."}, {"id": "OG001", "title": "Theophylline", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.\n\nTheophylline 400 mg: Participants will be assigned to theophylline once a day for 24 weeks"}, {"id": "OG002", "title": "Montelukast", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.\n\nMontelukast 10mg: Participants will be assigned to montelukast once a day for 24 weeks."}, {"id": "OG003", "title": "Fluticasone 250 mg/Salmeterol 50mg", "description": "Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.\n\nFluticasone 250 mg/salmeterol 50 mg: Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.07"}, {"groupId": "OG001", "value": "0.24", "spread": "0.20"}, {"groupId": "OG002", "value": "0.14", "spread": "0.15"}, {"groupId": "OG003", "value": "0.13", "spread": "0.18"}]}]}]}, {"type": "SECONDARY", "title": "Percent (%) Perdicted FEV1 Changes", "description": "Physiologic measures of % predicted FEV1", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent predicted FEV1", "timeFrame": "Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks. Median scores over the 24 weeks of treatment were compared", "groups": [{"id": "OG000", "title": "Ipratropium", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 0.02% solution, 2.5 ml via mini nebulizer for 24 weeks with placebo theophylline and placebo montelukast.\n\nIpratropium: Participants will be assigned to ipratropium 0.02% solution, 2.5 ml via mini nebulizer 3 times"}, {"id": "OG001", "title": "Theophylline", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.\n\nTheophylline: Participants will be assigned to theophylline 400 mg once a day for 24 weeks"}, {"id": "OG002", "title": "Montelukast", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.\n\nMontelukast 10mg: Participants will be assigned to montelukast 10 mg once a day for 24 weeks."}, {"id": "OG003", "title": "Fluticasone 250 mg/Salmeterol 50mg", "description": "Participants will be assigned to inhaled fluticasone 250 mg/salmeterol 50 mg twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.\n\nFluticasone 250 mg/salmeterol 50 mg:\n\nParticipants will be assigned to a 24 week treatment with inhaled fluticasone 250 mg /salmeterol 50"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.62", "spread": "7.89"}, {"groupId": "OG001", "value": "4.73", "spread": "7.72"}, {"groupId": "OG002", "value": "0.87", "spread": "10.57"}, {"groupId": "OG003", "value": "-5.71", "spread": "5.24"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "1 year", "eventGroups": [{"id": "EG000", "title": "Ipratropium", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 0.02% solution, 2.5 ml via mini nebulizer for 24 weeks with placebo theophylline and montelukast.\n\nIpratropium: Participants will be assigned to ipratropium 0.02% solution, 2.5 ml via mini nebulizer 3 times", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 4, "otherNumAtRisk": 5}, {"id": "EG001", "title": "Theophylline", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 300 mg once a day for 24 weeks with placebo tiotroprium and montelukast.\n\nTheophylline: Participants will be assigned to theophylline 300 mg once a day for 24 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 5, "otherNumAtRisk": 5}, {"id": "EG002", "title": "Montelukast", "description": "Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and tiotroprium.\n\nMontelukast 10mg: Participants will be assigned to montelukast 10 mg once a day for 24 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 5, "otherNumAffected": 5, "otherNumAtRisk": 5}, {"id": "EG003", "title": "Fluticasone 250 mg/Salmeterol 50mg", "description": "Participants will be assigned to inhaled fluticasone 250 mg/salmeterol 50 mg twice a day for 24 weeks with placebo theophylline, tiotroprium, and montelukast.\n\nFluticasone 250 mg/salmeterol 50 mg:\n\nParticipants will be assigned to a 24 week treatment with inhaled fluticasone 250 mg /salmeterol 50", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 5, "otherNumAtRisk": 5}], "seriousEvents": [{"term": "asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Participant hospitalized overnight with asthma exacerbation. Study drug stopped while overnight hospitalization and continued with randomized study drug and completed double blind portion of study.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "death", "organSystem": "Social circumstances", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Participant in the run-out phase with open label Advair 100/50 and was found dead. Autopsy found cause of that to be due to Phencyclidine and Cocaine Toxicity", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}], "otherEvents": [{"term": "migraine headache", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "migraine headache", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "viral infection", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "self-limiting viral infection", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 5}]}, {"term": "back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient back pain", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "drowsiness", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient drowsiness", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient rash", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "motor vehicle accident", "organSystem": "Social circumstances", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "motor vehicle accident with no serious injury", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "dry mouth", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient dry mouth", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient chest wall discomfort", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "urinary tract infection", "organSystem": "Renal and urinary disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "treated urinary tract infection with no recurrence", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient nausea", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient diarrhea", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient tachycardia", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "headache", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "musculoskeletal headache", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "edema", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "mild transient edema", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "skin lesion", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "stable keratosis", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "swollen hand", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient swollen hand", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}]}, {"term": "constipation", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient constipation", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "sprained finger", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "sprained finger, recovered without difficulty", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient lower extremity itching", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}, {"term": "iritis", "organSystem": "Eye disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "transient viral", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Joe Ramsdell", "organization": "University of California San Diego", "email": "jramsdell@ucsd.edu", "phone": "619-543-7241"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000013806", "term": "Theophylline"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000009241", "term": "Ipratropium"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000010726", "term": "Phosphodiesterase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058915", "term": "Purinergic P1 Receptor Antagonists"}, {"id": "D000058914", "term": "Purinergic Antagonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M12193", "name": "Ipratropium", "asFound": "Levonorgestrel", "relevance": "HIGH"}, {"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M16573", "name": "Theophylline", "asFound": "Pituitary", "relevance": "HIGH"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Blood culture", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M13629", "name": "Phosphodiesterase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}